Literature DB >> 22974393

Proteomic classification of breast cancer.

Dalia Kamel1, Bernadette Brady, Adel Tabchy, Gordon B Mills, Bryan Hennessy.   

Abstract

Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme-linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22974393     DOI: 10.2174/138945012803530080

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  10 in total

1.  Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

Authors:  Pradip De; Yuling Sun; Jennifer H Carlson; Lori S Friedman; Brian R Leyland-Jones; Nandini Dey
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

2.  Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.

Authors:  Ozgur Sahin; Qingfei Wang; Samuel W Brady; Kenneth Ellis; Hai Wang; Chia-Chi Chang; Qingling Zhang; Preety Priya; Rui Zhu; Stephen T Wong; Melissa D Landis; William J Muller; Francisco J Esteva; Jenny Chang; Dihua Yu
Journal:  Cell Res       Date:  2014-03-28       Impact factor: 25.617

3.  Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.

Authors:  Nandini Dey; Yuliang Sun; Jennifer H Carlson; Hui Wu; Xiaoqian Lin; Brian Leyland-Jones; Pradip De
Journal:  Am J Cancer Res       Date:  2016-03-15       Impact factor: 6.166

Review 4.  Rab25 in cancer: a brief update.

Authors:  Shreya Mitra; Kwai W Cheng; Gordon B Mills
Journal:  Biochem Soc Trans       Date:  2012-12-01       Impact factor: 5.407

5.  A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy.

Authors:  Nandini Dey; Jennifer Aske; Xiaoqian Lin; Yuliang Sun; Brian Leyland-Jones; Lori Friedman; Pradip De
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  Modeling precision treatment of breast cancer.

Authors:  Anneleen Daemen; Obi L Griffith; Laura M Heiser; Nicholas J Wang; Oana M Enache; Zachary Sanborn; Francois Pepin; Steffen Durinck; James E Korkola; Malachi Griffith; Joe S Hur; Nam Huh; Jongsuk Chung; Leslie Cope; Mary Jo Fackler; Christopher Umbricht; Saraswati Sukumar; Pankaj Seth; Vikas P Sukhatme; Lakshmi R Jakkula; Yiling Lu; Gordon B Mills; Raymond J Cho; Eric A Collisson; Laura J van't Veer; Paul T Spellman; Joe W Gray
Journal:  Genome Biol       Date:  2013       Impact factor: 13.583

7.  Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.

Authors:  Erika J Lampert; John L Hays; Elise C Kohn; Christina M Annunziata; Lori Minasian; Minshu Yu; Nicolas Gordon; Tristan M Sissung; Victoria L Chiou; William D Figg; Nicole Houston; Jung-Min Lee
Journal:  Oncotarget       Date:  2019-04-23

8.  A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Authors:  Kimberly C Wiegand; Bryan T Hennessy; Samuel Leung; Yemin Wang; Zhenlin Ju; Mollianne McGahren; Steve E Kalloger; Sarah Finlayson; Katherine Stemke-Hale; Yiling Lu; Fan Zhang; Michael S Anglesio; Blake Gilks; Gordon B Mills; David G Huntsman; Mark S Carey
Journal:  BMC Cancer       Date:  2014-02-22       Impact factor: 4.430

9.  Screening and functional analysis of a differential protein profile of human breast cancer.

Authors:  Fu-Jun Liu; Xue-Bo Wang; Ai-Guo Cao
Journal:  Oncol Lett       Date:  2014-03-18       Impact factor: 2.967

10.  Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Authors:  Jung-Min Lee; John L Hays; Victoria L Chiou; Christina M Annunziata; Elizabeth M Swisher; Maria I Harrell; Minshu Yu; Nicolas Gordon; Tristan M Sissung; Jiuping Ji; William D Figg; Lori Minasian; Stanley Lipkowitz; Bradford J Wood; James Doroshow; Elise C Kohn
Journal:  Oncotarget       Date:  2017-03-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.